In this study, we generated GPC1-specific CAR-T cells from the variable regions of the anti-GPC1 mAb (clone: 1–12) that recognize both human and mouse GPC1, and evaluated their efficacy and safety, using not only tumor xenografts in immunodeficient mouse models but also immunocompetent syngeneic mouse models. Here, GPC1 is linked to neoplasm.